Skip to main content
. 2022 Jun 21;2022(6):CD015017. doi: 10.1002/14651858.CD015017.pub3

2.7. Analysis.

2.7

Comparison 2: Ivermectin for treating COVID‐19 in outpatient settings with asymptomatic or mild disease, Outcome 7: Quality of life (mental component) at up to 28 days